The 12-year manufacturing veteran redefines the supply chain by combining duty-paid local inventory in Germany, Spain, and Poland with industry-leading “Triple-Tank” technology.

SHENZHEN, China – ZOOY VAPE, a recognized innovator in the electronic cigarette manufacturing sector established in 2013, today announced a major strategic expansion of its European operations. The company has officially fully operationalized its logistics “Iron Triangle”—three strategic distribution hubs located in Germany, Spain, and Poland. This move is designed to offer European wholesalers a seamless, duty-paid supply chain with guaranteed 2-to-5-day delivery windows, effectively eliminating the long lead times and customs uncertainties associated with cross-border imports.

To celebrate this milestone, ZOOY is launching an exclusive “Partner Sample Program,” offering free sample kits to qualified distributors across the EU to demonstrate the quality of its newly certified product line.

Business Value Analysis: Speed is Cash Flow

In the highly competitive European vaping market, inventory turnover speed is critical. ZOOY’s new localized infrastructure addresses this head-on, shifting the paradigm from “Importing” to “Local Distribution.”

For wholesalers in key markets like Madrid, Berlin, Rome, and Warsaw, this logistics upgrade translates into tangible commercial value:

• Optimized Cash Flow: Partners no longer need to tie up capital in bulk orders that take weeks to arrive from China. ZOOY’s “Just-in-Time” delivery allows for smaller, more frequent restocking cycles.
• Risk Elimination: All stock in the Spain, Germany, and Poland hubs is fully Duty-Paid. This removes the risk of unexpected customs seizures or tariff fluctuations.
• Regional Precision:
  • The Spain Hub: Leveraging CTT and DPD carriers, serving Southern and Western Europe (Spain, Portugal, France, Italy) with delivery times as short as 2 days.
  • The Germany & Poland Hubs: Utilizing UPS and DPD, covering Central, Northern, and Eastern Europe, ensuring markets from the Netherlands to Romania receive stock within 3-5 business days.

Certified Safety: Compliance Backed by Rigorous Testing

As the demand for large-capacity disposables (Big Puffs) grows, so does the scrutiny on safety and regulatory compliance. ZOOY distinguishes itself by strictly adhering to European standards.

The company has secured full CE-EMC Certifications for its flagship high-puff models. According to recent test reports from Shenzhen Qiqing Technology Co., Ltd., key models such as the ZOOY VAPOR 22000 have passed stringent testing under standards EN IEC 55014-1:2021 and EN IEC 55014-2:2021. This certification confirms that ZOOY’s advanced electronics meet all electromagnetic compatibility requirements, ensuring battery stability and user safety even in high-wattage devices.

This commitment to compliance extends across the “High-Puff” range, including the ZOOY king triple 3 in 1 80k, ZOOY 6 in 1 120k, giving distributors the confidence to sell large-capacity devices in regulated markets.

Product Technology Deep Dive: The “Flavor & Cloud” Revolution

ZOOY is introducing two groundbreaking technologies to the European market, designed to solve the most common user complaints: flavor fatigue and weak performance.

1. The “Triple-Tank” System (Featured in ZOOY King TRIPLE 80000): Unlike standard dual-flavor devices that often suffer from cross-contamination, the King TRIPLE 80000 features a revolutionary Independent 3-Tank Architecture.

• How it Works: The device houses three physically separated e-liquid reservoirs ， each with its own vaporization channel.
• The Advantage: This ensures flavor mixing. A user can switch from a fruity profile to a mint profile instantly, with each puff tasting crisp and distinct. This innovation effectively combats “vaper’s tongue” (loss of taste sensation), keeping users engaged with the device for longer.

2. Advanced Mesh Coil Technology (Featured in SHISHA & BLAZE Series): To cater to the “E-Shisha” trend popular in Germany and Poland, ZOOY deploys Quad Mesh and Dual Mesh coil configurations.

• The Advantage: By increasing the heating surface area, these coils deliver rapid ramp-up times and consistent heat distribution. This results in a legitimate Direct-to-Lung (DTL) experience with dense cloud production and intense flavor reproduction that mimics traditional Shisha, but in a portable format.

Empowering Brands: Your OEM/ODM Factory Next Door

ZOOY is more than just a brand; it is a manufacturing powerhouse with a 6,500 square meter facility and over 12 years of experience serving top-tier industry giants like HQD, Smiss, and ALD.

ZOOY is now opening its Customization Services to European distributors.

• Market Adaptation: We can tweak flavor profiles to match specific regional preferences (e.g., sweeter notes for the UK, cooler notes for Germany).
• Private Labeling: Wholesalers can leverage ZOOY’s R&D capability to launch their own compliant brands, utilizing our CE-certified chassis as a foundation.

“We invite European brands to utilize our factory capabilities,” said the Sales Director. “Whether you need our ready-to-ship stock in 48 hours or a fully customized private label solution, ZOOY is your factory partner next door.”

Invitation to Partner

Verified wholesalers and distributors are invited to contact ZOOY immediately to request the latest European Warehouse Stock List and apply for a Free Sample Kit.

For media inquiries, wholesale catalogs, and sample requests, please contact:

Brand/Company Name: ZOOY

Contact Person Name: Mary

Contact Person Title: Sales Director

E-Mail: mary@zooyvape.com

Telephone/WhatsApp: +86 18124062975  

Address: No. 5 Yonghe Road, Shiyan Town, Bao’an District, Shenzhen, Guangdong Province 518108, China

Official Website: www.zooyvape.com

Social Links: https://www.facebook.com/profile.php?id=61581971165186

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.

In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile^[1]. 

In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million^[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.

The Product’s inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.

The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. 

Reference：

1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
2. Datas are from the China Insights Consultancy (CIC) report

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/